Victoria N. Parikh
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (7)
Cardiac fibrosis is a central pathological process in heart failure, yet the molecular mechanisms governing its spatial organization remain poorly defined. We developed an artificial intelligence (AI)-based phenotyping approach to decode the spatial organization of cardiac fibrosis from routine cardiac magnetic resonance imaging (MRI). We applied convolutional variational autoencoders (VAEs) and distributional metrics to native T1 maps from 50,239 UK Biobank participants. VAE-derived features predicted mortality with greater precision than standard T1 measures (C-index 0.614 vs. 0.547; likelihood ratio p = 2.9×10 -3 ), identifying spatial fibrosis patterns as independent prognostic indicators. Through genome-wide association studies, we identified genetic loci underlying T1 distribution metrics, implicating oxidative stress pathways (SOD2, GSS) and calcium signaling (CAMK2D, CALU). Pathway enrichment revealed distinct biological processes: T1 distributions reflected metabolic and coagulation activity, while spatial VAE dimensions reflected extracellular matrix organization and complement regulation. Mendelian randomization identified cathepsin S (CTSS) and extracellular matrix protein 1 (ECM1) as causal mediators with near-certain colocalization evidence (PP.H4>0.88), validated in an independent Icelandic cohort (n=35,559). FKBPL demonstrated causal effects on both T1 distributional and spatial features. Published preclinical studies show CTSS inhibition reduces collagen deposition and ventricular stiffening, ECM1 stabilizes extracellular matrix and prevents fibrosis, and FKBPL peptides attenuate fibroblast activation. These findings highlight tractable pathways for therapeutic modulation of myocardial fibrosis.
Year:
2025
Background Desmoplakin (DSP) cardiomyopathy, caused by variants in the gene DSP , is a unique subtype of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathies. Specific diagnostic and disease staging criteria have yet to be developed for DSP cardiomyopathy. Objective Utilizing a large cohort of DSP cardiomyopathy patients and their genotype-positive family members, this study aims to develop diagnostic and disease staging criteria for DSP cardiomyopathy. Methods Patients from the DSP -ERADOS Network with complete rhythm monitoring, electrocardiogram and cardiac magnetic resonance imaging were enrolled. Diagnostic criteria were assessed in initially-presenting patients (probands) and their genotype-positive family members. Early disease criteria (with preserved left ventricular ejection fraction, LVEF) were integrated into standard LVEF-based classifications. Diagnostic and staging criteria were assessed by time-event analyses (major ventricular arrhythmia and heart failure events). Results A total of 605 patients with complete diagnostic testing were included (mean age 40 yr, 60% female, 40% probands). The most prevalent disease features in probands were premature ventricular contractions (PVCs) >500/24hr (66%), nonsustained ventricular tachycardia (NSVT, 29%), LV late gadolinium enhancement (LGE, 53%), and reduced LVEF (44%). The presence of any one of these features was 97% sensitive for diagnosis (along with a DSP pathogenic variant) and were therefore considered as diagnostic criteria. Using these criteria, 77% of genotype-positive family members were considered clinically affected. Isolated right ventricular (RV) involvement occurred in only 0.7%. The absence of diagnostic criteria identified a low-risk group (composite event rate 0.8%/year, p 50%, HR 2.7, p=0.04; intermediate: LVEF 41-49%, HR 3.7, p=0.009; advanced: LVEF <40% HR 10.3, p<0.001). LGE was mostly subepicardial (87%). Circumferential (ring-like) LGE was more frequent in intermediate or advanced vs early disease (66% vs 48%, p<0.001). Conclusion This study identifies genotype-specific diagnostic and disease staging criteria for DSP cardiomyopathy that improve identification of risk for both heart failure and sustained ventricular arrhythmias. This work highlights how gene-specific criteria may be used to refine diagnosis and staging for cardiomyopathy subtypes – a critical step as gene-targeted treatments move toward clinical trials.
Year:
2025
Extrachromosomal-circular DNA (eccDNA) are circular-DNA elements that are implicated in cellular processes such as genomic diversification and instability, along with other genomic mechanisms. However, their structure and chromatinization state is poorly understood. Here we identified a 358-bp circular micro-eccDNA molecule derived from the human Titin gene, which was selected for this study based on its size and sequence characteristics, and used atomistic molecular dynamics simulations to study its interaction with nucleosomes and corresponding topological state. We show the presence or absence of bound nucleosomes provides a topological switch between intact and denatured DNA.
Year:
2025
Background An estimated 1 in 500 people live with hypertrophic cardiomyopathy (HCM), a disease for which genetic diagnosis can identify family members at risk, and increasingly guide therapy. Mutations in the myosin binding protein C3 ( MYBPC3 ) gene account for a significant proportion of HCM cases. However, many of these variants are classified as variants of uncertain significance (VUS), complicating clinical decision-making. Scalable methods for variant interpretation in disease-specific cell types are crucial for understanding variant impact and uncovering disease mechanisms. Methods We developed a scaled multidimensional mapping strategy to evaluate the functional impact of variants across a critical domain of MYBPC3. We incorporate saturation base editing at the native MYBPC3 locus, a long-read RNA sequencing-enabled assay of variant splice effects, and measurements of HCM-relevant phenotypes, including MYBPC3 abundance, hypertrophic signaling, and ubiquitin-proteasome function in human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). Results Our multidimensional mapping strategy enabled high-resolution functional analysis of MYBPC3 variants in iPSC-CMs. Targeted transient base editing generated a comprehensive variant library at the native locus, capturing diverse variant effects on cellular HCM-relevant phenotypes. Our massively parallel splicing assay identified novel splice-disrupting variants. Integration of functional assays revealed that decreased MYBPC3 abundance is a key driver of HCM-related phenotypes. In parallel, downregulation of protein degradation was observed as a compensatory response to MYBPC3 loss of function, and novel disease mechanisms were identified for missense variants near a critical binding domain, underscoring their contribution to pathogenesis. Bayesian estimates of variant effects enable the reclassification of clinical variants. Conclusions This work provides a platform for extending genome engineering in iPSCs to multiplexed assays of variant effects across diverse disease-relevant cellular phenotypes, enhancing the understanding of variant pathogenicity and uncovering novel biological mechanisms that could inform therapeutic strategies.
Year:
2025
BACKGROUND: Septal reduction therapy (SRT) provides substantial symptomatic improvement in patients with obstructive hypertrophic cardiomyopathy (HCM). However, long-term disease course after SRT and predictors of adverse outcomes have not been systematically examined. METHODS: Data from 13 high clinical volume HCM centers from the international SHARE (Sarcomeric Human Cardiomyopathy Registry) were analyzed. Patients were followed from the time of SRT until last follow-up or occurrence of heart failure (HF) composite outcome (cardiac transplantation, implantation of a left ventricular assist device, left ventricular ejection fraction <35%, development of New York Heart Association class III or IV symptoms), ventricular arrhythmias composite outcome (sudden cardiac death, resuscitated cardiac arrest, or appropriate implantable cardioverter defibrillator therapy), or HCM-related death. Cox proportional hazards models were used to identify predictors of outcome. RESULTS: Of the 10 225 patients in SHARE, 1832 (18%; 968 [53%] male) underwent SRT, including 455 (25%) with alcohol septal ablation and 1377 (75%) with septal myectomy. The periprocedural 30-day mortality rate was 0.4% (8 of 1832) and 1499 of 1565 (92%) had a maximal left ventricular outflow tract gradient <50 mm Hg at 1 year. After 6.8 years (range, 3.4–9.8 years; 12 565 person-years) from SRT, 77 (4%) experienced HCM-related death (0.6% per year), 236 (13%) a composite HF outcome (1.9% per year), and 87 (5%) a composite ventricular arrhythmia outcome (0.7% per year). Among adults, older age at SRT was associated with a higher incidence of HCM death (hazard ratio, 1.22 [95 CI, 1.1–1.3]; P <0.01) and the HF composite (hazard ratio, 1.14 [95 CI, 1.1–1.2] per 5-year increase; P <0.01) in a multivariable model. Female patients also had a higher risk of the HF composite after SRT (hazard ratio, 1.4 [95 CI, 1.1–1.8]; P <0.01). De novo atrial fibrillation occurred after SRT in 387 patients (21%). Among pediatric patients followed for a median of 13 years after SRT, 26 of 343 (16%) developed the HF composite outcome, despite 96% being free of recurrent left ventricular outflow tract obstruction. CONCLUSIONS: Successful short- and long-term relief of outflow tract obstruction was observed in experienced multidisciplinary HCM centers. A subset of patients progressed to develop HF, but event-free survival at 10 years was 83% and ventricular arrhythmias were rare. Older age, female sex, and SRT during childhood were associated with a greater risk of developing HF.
Year:
2024
Background: Hypertrophic cardiomyopathy (HCM) is an inherited cardiac condition affecting ~1 in 500 and exhibits marked genetic heterogeneity. Previously published in 2019, 57 HCM-associated genes were curated providing the first systematic evaluation of gene-disease validity. Here we report work by the ClinGen Hereditary Cardiovascular Disorders Gene Curation Expert Panel (HCVD-GCEP) to reappraise the clinical validity of previously curated and new putative HCM genes. Methods: The ClinGen systematic gene curation framework was used to re-classify the gene-disease relationships for HCM and related syndromic entities involving left ventricular hypertrophy. Genes previously curated were included if their classification was not definitive, and if the time since curation was >2-3 years. New genes with literature assertions for HCM were included for initial evaluation. Existing genes were curated for new inheritance patterns where evidence existed. Curations were presented on twice monthly calls, with the HCVD-GCEP composed of 29 individuals from 21 institutions across 6 countries. Results: Thirty-one genes were re-curated and an additional 5 new potential HCM-associated genes were curated. Among the re-curated genes, 17 (55%) genes changed classification: 1 limited and 4 disputed (from no known disease relationship), 9 disputed (from limited), and 3 definitive (from moderate). Among these, 3 (10%) genes had a clinically relevant upgrade, including TNNC1, a 9th sarcomere gene with definitive HCM association. With new evidence, two genes were curated for multiple inheritance patterns (TRIM63, disputed for autosomal dominant but moderate for autosomal recessive; ALPK3, strong for autosomal dominant and definitive for recessive). CSRP3 was curated for a semi-dominant mode of inheritance (definitive). Nine (29%) genes were downgraded to disputed, further discouraging clinical reporting of variants in these genes. Five genes recently reported to cause HCM were curated: RPS6KB1 and RBM20 (limited), KLHL24 and MT-TI (moderate), and FHOD3 (definitive). Conclusions: We report 29 genes with definitive, strong or moderate evidence of causation for HCM or isolated LVH, including sarcomere, sarcomere-associated and syndromic conditions.
Year:
2024
Year:
2023
Collaborators (61)
Sharlene Day
Associate Professor
University of Pennsylvania
Arthur A M Wilde
University of Amsterdam
Courtney Thaxton
Associate Professor
University of North Carolina at Chapel Hill
Nisha Gilotra
Assistant Professor of Medicine
Johns Hopkins University School of Medicine
Roddy Walsh
Researcher/Lecturer
City, University of London
Anjali T. Owens
Assistant Professor, Clinician-Educator
University of Pennsylvania Perelman School of Medicine
Firat Duru
-
Kristina Haugaa
Professor
University of Oslo
A.s Amin
Cardiologist
Amsterdam University Medical Centers
Eric Smith
University of Michigan
Francois Haddad
Associate Professor of Cardiovascular Medicine
Stanford University
Julia Cadrin-Tourigny
Clinical Assistant Professor
Université de Montréal
J. Peter van Tintelen
Head Department; clinical geneticist
Universitair Medisch Centrum Utrecht
Elizabeth M. McNally
Director
Northwestern University Feinberg School of Medicine
Matthew Taylor
Professor
University of Colorado Anschutz Medical Campus
Lia Crotti
Director of the Cardiological Rehabilitation Unit, San Luca Hospital
IRCCS Istituto Auxologico Italiano
Sing-Chien Yap
Researcher
Erasmus University Rotterdam
Michela Casella
Researcher
Università Politecnica delle Marche
Sarah Harris
Professor of Biological and Materials Physics
University of Sheffield
Elizabeth Jordan
Ohio State University
Michelle Michels
Researcher
Erasmus University Rotterdam
Qianru Wang
Associate Professor (non-tenured)
Shanghai Jiao Tong University
Dan M Roden
Professor
Vanderbilt University Medical Center
Adam Helms
Assistant Professor
University of Michigan
John Stendahl
Yale University
R Foo
Professor
National University of Singapore (NUS)
Andrew Glazer
Assistant Professor
Vanderbilt University Medical Center
Petros Syrris
University College London
B. Callewaert
Associate Professor
Ghent University
Iacopo Olivotto
University of Florence
James Ware
Professor
Imperial College London
Marco Merlo
University of Trieste
Marina Cerrone
Research Assistant Professor of Medicine
NYU School of Medicine
Jodie Ingles
Head, Ingles Lab
Garvan Institute of Medical Research
Matthew Wheeler
Associate Professor
Stanford University
Thomas Ryan
Associate Professor - Clinical
Cincinnati Children's Hospital Medical Center
Andrew Z Fire
Professor
Stanford University School of Medicine
Gianfranco Sinagra
University of Trieste
Laura Muiño Mosquera
Staf
Ghent University Hospital
Barbara Bauce
Associate Professor
University of Padova
Hugh Calkins
Johns Hopkins University School of Medicine
Cynthia James
Associate Professor
Johns Hopkins University
Nosheen Reza
University of Pennsylvania
Andrew Landstrom
Professor
Duke University School of Medicine
Euan A. Ashley
Professor
Stanford University School of Medicine
Joseph Rossano
Children's Hospital of Philadelphia
Thomas Bishop
associate professor
Louisiana Tech University
cristina basso
Professore Ordinario di Anatomia Patologica
University of Padova
Kalliopi Pilichou
Associate Professor
University of Padua
Ardan M. Saguner
-
Stephen Levene
Professor
University of Texas at Dallas
Luisa Mestroni
Professor of Medicine
University of Colorado Anschutz Medical Campus
Juan Gimeno Blanes
Associate Professor
Universidad de Murcia
Marco Schiavone
Clinical Scientist
Centro Cardiologico Monzino
Richard D. Bagnall
University of Sydney
Rachel Lampert
Yale University School of Medicine
Ashwin S. Nathan
-
Giovanni Peretto
Vita-Salute San Raffaele University
Perry Elliott
University College London
David Staudt
Stanford University
Calum MacRae
Professor
Harvard University
Make your next move.
Prepare your application
Review drafts before you send them.